ROSSETTI B.

Last name: ROSSETTI B.

2019 (v1)

Publication

Metadata-only

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort

Modica S. Rossetti B. Lombardi F.

Objectives: The aim of the study was to analyse the prevalence of integrase resistance mutations in integrase strand transfer inhibitor (INSTI)-experienced HIV-1-infected patients and its predictors. Methods: We selected HIV-1 integrase sequences from the Antiviral Response Cohort Analysis (ARCA) database, derived from INSTI-experienced...

Uploaded on: April 14, 2023
2023 (v1)

Publication

Metadata-only

Trend over time of HIV-1 drug resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and their drivers: A cohort study from Antiviral Response Cohort Analysis (ARCA)

Rancan I. Cassol C. Graziani L.

No description

Uploaded on: February 4, 2024
2019 (v1)

Publication

Metadata-only

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study

Rossetti B. Gagliardini R. Sterrantino G.

No description

Uploaded on: April 14, 2023
2021 (v1)

Publication

Metadata-only

Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy

Fabbiani M. Borghetti A. Squillace N.

BACKGROUND: We explored predictors of CD4/CD8 ratio improvement and optimal immunological recovery (OIR) after initiation of antiretroviral therapy (ART) in naive people living with HIV (PLWH). METHODS: Retrospective multicenter study including naive PLWH starting ART with 2 nucleos(t)ide reverse transcriptase inhibitors + 1 integrase strand...

Uploaded on: April 14, 2023
2017 (v1)

Publication

Metadata-only

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial

Rossetti B. Gagliardini R. Meini G.

Objectives: Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48. Methods: Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART (continuation...

Uploaded on: April 14, 2023

ROSSETTI B.

Recent uploads